K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · MERCK & CO. INC.
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-20 | MRK | MERCK & CO. INC. | THE NICKLES GROUP, LLC | $70K | Issues related to pharmacy benefit management reforms. Issues related to vaccine policy. Issues related to supply chain and domestic manufacturing capacity. Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. Issues related to pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing. Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes. Issues related to tariffs. |
| 2026-04-20 | MRK | MERCK & CO. INC. | TODD STRATEGY GROUP | $50K | 340B issues. Antimicrobial resistance. Supply Chain. Vaccine issues. Food and Drug Administration issues. Drug Pricing. S.864: HELP Copays Act. |
| 2026-04-20 | MRK | MERCK & CO. INC. | AVENUE SOLUTIONS | $50K | Issues related to vaccines; Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders and expiring Advanced Premium Tax Credits (APTC) Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to cyclic peptides; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to the implementation of the Inflation Reduction Act of 2022; Issues related to Senate Finance Dear Colleague process |
| 2026-04-20 | MRK | MERCK & CO. INC. | CROSSROADS STRATEGIES, LLC | $40K | Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals. Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues. Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order. General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) imp |
| 2026-04-18 | MRK | MERCK & CO. INC. | W STRATEGIES, LLC | $50K | Education around access to vaccines. Public Law 119-21: One Big Beautiful Bill Act. |
| 2026-01-20 | MRK | MERCK & CO. INC. | AVENUE SOLUTIONS | $50K | Issues related to vaccines; Expiring healthcare extenders Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to cyclic peptides; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to the implementation of the Inflation Reduction Act of 2022 |
| 2026-01-20 | MRK | MERCK & CO. INC. | THE NICKLES GROUP, LLC | $50K | Issues related to pharmacy benefit management reforms. Issues related to vaccine policy. Issues related to supply chain and domestic manufacturing capacity. Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 946/S. 1862, ORPHAN Cures Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. Issues related to pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing. Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes. Issues related to tariffs. |
| 2026-01-20 | MRK | MERCK & CO. INC. | HARBINGER STRATEGIES, LLC | $50K | Issues related to international tax policy. |
| 2026-01-20 | MRK | MERCK & CO. INC. | W STRATEGIES, LLC | $50K | Education around access to vaccines. Public Law 119-21: One Big Beautiful Bill Act. |
| 2026-01-20 | MRK | MERCK & CO. INC. | TODD STRATEGY GROUP | $50K | 340B issues. Antimicrobial resistance. Supply Chain. Vaccine issues. Food and Drug Administration issues. Drug Pricing. S.864 - HELP Copays Act. |
| 2026-01-20 | MRK | MERCK & CO. INC. | CROSSROADS STRATEGIES, LLC | $40K | Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues. Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2026 National Defense Authorization Act, S.2296/H.R.3838/P.L.119-60), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order. General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation. Issues related to tax |
| 2025-10-20 | MRK | MERCK & CO. INC. | W STRATEGIES, LLC | $50K | Public Law 119-21: One Big Beautiful Bill Act. H.R.1492: EPIC Act. Education around access to vaccines. |
| 2025-10-20 | MRK | MERCK & CO. INC. | AVENUE SOLUTIONS | $50K | Issues related to vaccines; Expiring healthcare extenders Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to cyclic peptides; Issues related to Most Favored Nation (MFN) drug pricing proposal |
| 2025-10-20 | MRK | MERCK & CO. INC. | TODD STRATEGY GROUP | $50K | 340B issues. Antimicrobial resistance. Supply Chain. Vaccine issues. Food and Drug Administration issues. Drug Pricing. S.864 - HELP Copays Act. |
| 2025-10-20 | MRK | MERCK & CO. INC. | HARBINGER STRATEGIES, LLC | $50K | Issues related to international tax policy. |
| 2025-10-18 | MRK | MERCK & CO. INC. | CROSSROADS STRATEGIES, LLC | $40K | Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals. H.R.1, One Big Beautiful Bill Act (P.L.119-21), all bio-pharmaceutical related provisions. Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues. Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2026 National Defense Authorization Act, S.2296/H.R.3838), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order. General issues related to Medicare and Medicaid, |
| 2025-10-16 | MRK | MERCK & CO. INC. | THE NICKLES GROUP, LLC | $50K | Issues related to pharmacy benefit management reforms. Issues related to vaccine policy. Issues related to supply chain and domestic manufacturing capacity. Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 946/S. 1862, ORPHAN Cures Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to drug pricing and pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing. H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes. Issues related to tariffs. |
| 2025-07-21 | MRK | MERCK & CO. INC. | AVENUE SOLUTIONS | $50K | Health care issues in H.R.1, To provide for reconciliation pursuant to title II of H. Con. Res. 14 (Public Law No: 119-21); Issues related to vaccines Value of prescription drugs; Issues related to Medicare Parts B and D; Issues related to Medicare and Medicaid coverage and reimbursement; H.R. 946/S. 1862, ORPHAN Cures Act; Issues related to cyclic peptides; Issues related to Average Sales Price (ASP) and Part B Medicare negotiation; Issues related to Most Favored Nation (MFN) drug pricing proposal; H.R.4299, Protecting Patient Access to Cancer and Complex Therapies Act |
| 2025-07-21 | MRK | MERCK & CO. INC. | HARBINGER STRATEGIES, LLC | $50K | Issues related to international tax policy. |
| 2025-07-21 | MRK | MERCK & CO. INC. | CROSSROADS STRATEGIES, LLC | $40K | General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. Issues related to tax reform; R&D tax credit; international taxation; Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.1, One Big Beautiful Bill Act. Issues related to pharmaceutical IP, supply chain, and tariffs. H.R.1, One Big Beautiful Bill Act, all bio-pharmaceutical related provisions. Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues. Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2026 National Defense Authorization Act), antimicrobial resistance, VICP Program, and PBM reform; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; Infl |
| 2025-07-20 | MRK | MERCK & CO. INC. | TODD STRATEGY GROUP | $40K | 340B issues. Antimicrobial resistance. Supply Chain. Vaccine issues. Food and Drug Administration issues. Drug Pricing. S.864 - HELP Copays Act. |
| 2025-07-18 | MRK | MERCK & CO. INC. | W STRATEGIES, LLC | $50K | H.R.1 - One Big Beautiful Bill Act. H.R.1492: EPIC Act. |
| 2025-07-18 | MRK | MERCK & CO. INC. | BROWNSTEIN HYATT FARBER SCHRECK, LLP | $0 | |
| 2025-07-17 | MRK | MERCK & CO. INC. | THE NICKLES GROUP, LLC | $50K | Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 946/S. 1862, ORPHAN Cures Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. H.R.1, One Big Beautiful Bill Act, as it relates to drug pricing and pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing. H.R. 1, One Big Beautiful Bill Act, as it relates to corporate taxes. Issues related to tariffs. Issues related to pharmacy benefit management reforms. Issues related to vaccine policy. Issues related to supply chain and domestic manufacturing capacity. |
| 2025-04-21 | MRK | MERCK & CO. INC. | AVENUE SOLUTIONS | $50K | S. 891, Bipartisan Health Care Act; H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (PL 119-4); Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation Value of prescription drugs; Issues related to Medicare Parts B and D; Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation; Protecting Patient Access to Cancer and Complex Therapies Act; H.R. 1672, Maintaining Investments in New Innovation Act; Biosimilars Access and Affordability Act; H.R. 2484, Seniors Access to Critical Medications Act; H.R. 946, ORPHAN Cures Act |
| 2025-04-21 | MRK | MERCK & CO. INC. | HARBINGER STRATEGIES, LLC | $50K | Issues related to international tax policy. |
| 2025-04-21 | MRK | MERCK & CO. INC. | TODD STRATEGY GROUP | $40K | 340B issues. Antimicrobial resistance. Supply Chain. Vaccine issues. Food and Drug Administration issues. Drug Pricing. S.864 - HELP Copays Act. |
| 2025-04-21 | MRK | MERCK & CO. INC. | CROSSROADS STRATEGIES, LLC | $40K | Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2026 National Defense Authorization Act), antimicrobial resistance, VICP Program, and PBM reform; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act. General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. Issues related to tax reform. Inflation Reduction Act of 2022 (P.L.117-169) implementation; issues related to international taxation. Issues related to R&D tax credit. Issues related to pharmaceutical IP, supply chain, and tariffs. H.R.1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (P.L.119-4) |
| 2025-04-18 | MRK | MERCK & CO. INC. | W STRATEGIES, LLC | $50K | Implementation of H.R.5376 - Inflation Reduction Act of 2022. H.R.1492: EPIC Act. Education around the Vaccine Injury Compensation Program. PBM reform legislation including efforts to delink fees in Medicare Part D. |
| 2025-04-18 | MRK | MERCK & CO. INC. | BROWNSTEIN HYATT FARBER SCHRECK, LLP | $0 | |
| 2025-04-17 | MRK | MERCK & CO. INC. | THE NICKLES GROUP, LLC | $50K | Issues related to pharmacy benefit management reforms. Issues related to vaccine policy. Issues related to supply chain and domestic manufacturing capacity. Issues related to drug pricing and implementation of the Inflation Reduction Act. Issues related to the extension of the Tax Cut and Jobs Act provisions impacting corporations. Issues related to tariffs. |
| 2025-02-14 | MRK | MERCK & CO. INC. | THE NICKLES GROUP, LLC | $0 | Issues related to prescription drugs. Issues related to tax policy. Issues related to prescription drugs. Issues related to tax policy. Issues related to prescription drugs. Issues related to tax policy. Issues related to prescription drugs. Issues related to tax policy. |
| 2025-01-31 | MRK | MERCK & CO. INC. | HARBINGER STRATEGIES, LLC | $0 | Issues related to international tax policy. |
| 2025-01-21 | MRK | MERCK & CO. INC. | W STRATEGIES, LLC | $50K | Implementation of H.R.5376 - Inflation Reduction Act of 2022. H.R.10545 - American Relief Act, 2025 as it relates to PBM reform. Education around the Vaccine Injury Compensation Program. H.R.5378 - Lower Costs, More Transparency Act. PBM reform legislation including efforts to delink fees in Medicare Part D. |
| 2025-01-21 | MRK | MERCK & CO. INC. | AVENUE SOLUTIONS | $50K | Antibiotics/stewardship; S.1355/H.R.2940, PASTEUR Act of 2023; Issues related to the Vaccine Injury Compensation Program (VICP); Issues related to Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization; Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation; Issues related to HPV vaccine and ACIP recommendations; Issues related to 340b; Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; H.R. 10545, American Relief Act, 2025 Value of prescription drugs; Issues related to Medicare Parts B and D; Issues related to Medicare and Medicaid coverage and reimbursement |
| 2025-01-21 | MRK | MERCK & CO. INC. | CROSSROADS STRATEGIES, LLC | $40K | Issues related to appropriations and federal health programs; reimbursement issues; H.R.9027/S.4690, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025; H.R.9029/S.4942, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025; H.R.10445, Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025; H.R.10545, American Relief Act, 2025. Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues. Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program, antimicrobial resistance legislation, and VICP Program; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; H.R |
| 2025-01-20 | MRK | MERCK & CO. INC. | BROWNSTEIN HYATT FARBER SCHRECK, LLP | $0 |